- cafead Jun 08, 2022 at 10:52: AM
via Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting the potential of more than 80 new regulatory approvals in oncology through 2028.
Merck showcased its oncology pipeline at the American Society of Clinical Oncology meeting in Chicago. The company presented data from nearly 120 abstracts in more than 25 cancer types. Over the past decade, Merck’s oncology pipeline has exploded, driven by Keytruda, which is predicted to become the world’s top-selling drug after AbbVie’s Humira loses patent protection next year.
article source
Merck showcased its oncology pipeline at the American Society of Clinical Oncology meeting in Chicago. The company presented data from nearly 120 abstracts in more than 25 cancer types. Over the past decade, Merck’s oncology pipeline has exploded, driven by Keytruda, which is predicted to become the world’s top-selling drug after AbbVie’s Humira loses patent protection next year.
article source